Genentech Reports P-III Study (IMbrave050) Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) for Early-Stage Liver Cancer
Shots:
- The P-III study (IMbrave050) evaluating Tecentriq (1200mg, q3w) + Avastin (15mg/kg, q3w) vs active surveillance in a ratio (1:1) in 662 patients with HCC who are at high risk of recurrence
- The trial met its 1EPs of RFS at the prespecified interim analysis & showed an improvement in RFS in the ITT population, OS data were immature at the time of interim analysis & follow-up will continue to the next analysis. The results will be presented at an upcoming medical meeting
- The safety was consistent with the known safety profile of each therapeutic agent. The company intends to discuss the results with health authorities, incl. the US FDA & EMA & has an extensive development program incl. multiple ongoing & planned P-III studies across different cancers indications
Ref: Genentech | Image: Genentech
Related News:- Roche Reports P-III (IMscin001) Study Results of Subcutaneous Formulation of Tecentriq for the Treatment of Non-Small Cell Lung Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
